Linda Brent, PhD, MBA, Executive Director, Parsemus Foundation
$200,000 / 2 years Awarded January 2019 |
Revolution ContraceptivesSan Francisco, CA
About
Revolution Contraceptives has a social mission of empowering men worldwide to better control their reproduction with a reliable, safe, cost-effective, and reversible contraceptive. The company’s first contraceptive product, Vasalgel, is in development. Revolution Contraceptives was spun out of the Parsemus Foundation, which works to create meaningful improvements in human and animal health and welfare by advancing innovative and neglected medical research. Our Grant
MCI’s support helps Revolution Contraceptives advance Vasalgel toward human trials. The planned evaluations will be based on contraceptive effectiveness, procedural simplicity, reversibility, and safety. This proof-of-concept study will build on results from earlier preclinical studies and should support a future application for clinical trials in men. Vasalgel is intended to be a long-acting, non-hormonal contraceptive with a significant advantage over vasectomy in that it is likely to be more reversible and have fewer side effects post-procedure. The procedure is similar to a no-scalpel vasectomy, except the vas deferens (the tube the sperm swim through) is injected with a hydrogel, rather than being cut as is done in vasectomy. If a man wishes to restore the flow of sperm, whether after months or years, he may receive an injection in the office setting that removes the hydrogel. |
Publications
Colagross-Schouten, Angela, Marie-Josee Lemoy, Rebekah I. Keesler, Elaine Lissner, and Catherine A. VandeVoort. “The Contraceptive Efficacy of Intravas Injection of Vasalgel TM for Adult Male Rhesus Monkeys.” Basic and Clinical Andrology 27, no. 1 (December 2017): 4. https://doi.org/10.1186/s12610-017-0048-9.
Waller, Donald, David Bolick, Elaine Lissner, Christopher Premanandan, and Gary Gamerman. “Reversibility of Vasalgel TM Male Contraceptive in a Rabbit Model.” Basic and Clinical Andrology 27, no. 1 (December 2017): 8. https://doi.org/10.1186/s12610-017-0051-1.
Waller, Donald, David Bolick, Elaine Lissner, Christopher Premanandan, and Gary Gamerman. “Azoospermia in Rabbits Following an Intravas Injection of Vasalgel TM.” Basic and Clinical Andrology 26 (2016): 6. https://doi.org/10.1186/s12610-016-0033-8.
Colagross-Schouten, Angela, Marie-Josee Lemoy, Rebekah I. Keesler, Elaine Lissner, and Catherine A. VandeVoort. “The Contraceptive Efficacy of Intravas Injection of Vasalgel TM for Adult Male Rhesus Monkeys.” Basic and Clinical Andrology 27, no. 1 (December 2017): 4. https://doi.org/10.1186/s12610-017-0048-9.
Waller, Donald, David Bolick, Elaine Lissner, Christopher Premanandan, and Gary Gamerman. “Reversibility of Vasalgel TM Male Contraceptive in a Rabbit Model.” Basic and Clinical Andrology 27, no. 1 (December 2017): 8. https://doi.org/10.1186/s12610-017-0051-1.
Waller, Donald, David Bolick, Elaine Lissner, Christopher Premanandan, and Gary Gamerman. “Azoospermia in Rabbits Following an Intravas Injection of Vasalgel TM.” Basic and Clinical Andrology 26 (2016): 6. https://doi.org/10.1186/s12610-016-0033-8.
